Group items tagged

The British Generic Manufacturers Association (BGMA) on Monday alerted the Health and Social Care Committee that medicines shortages have increased and are "around double what they were a year ago." BGMA chief executive Mark Samuels told the committee that they have been highlighting the medicine shortage risk to ministers since July 2021 and the association is "very concerned" about the current situation. "We've been monitoring it for several years now, and as you saw in the written evidence, shortages have increased. They're around double what they were a year ago. We have them at 101 shortages in February this year," said Samuels. Dr Rick Greville, director of distribution and supply at the Association of the British Pharmaceutical Industry (ABPI), highlighted that the problem of drug shortages in the UK is a "long-standing issue" and the scarcity of certain medications "continues to be challenging".

Long waits for an ambulance or surgery led to the death of 112 people, and nearly 8,000 more people suffered harm while waiting for help in England last year. The data from NHS England, obtained by The Guardian, show that patient deaths arising directly from care delays have risen more than fivefold over the last three years. In 2019, there were 21 patient deaths due to NHS care delays, and 96 people suffered "severe harm" as compared to 152 last year. Adult mental health care was mostly affected with 471 patients experiencing harm due to delays, followed by childbirth care (253), eye problems (221), and trauma and general surgery (207). There has been increase of 97 percent in the overall number of people suffering some degree of harm, from 3,979 in 2019 to 7,856 in 2022.

There were an estimated 408,700 hospital admissions due to smoking in 2022-23, an increase of 4.8 per cent from 389,800 in 2021-22, latest statistics published by NHS England have shown. In 2020-21, there were 314,100 admissions attributed to smoking, which was consistent with fewer hospital admissions overall that year, according to the health service's Statistics on Public Health, 2023 report. However, smoking-related admissions in each of the past three years remained lower than in 2019-20, prior to the Covid pandemic, when there were 446,400 cases. Smoking accounted for around one in six (16 per cent) of all hospital admissions for respiratory diseases last year, eight per cent of all admissions for cancers and seven percent of admissions for cardiovascular diseases.

A drug dealer who was operating as an "unlicensed chemist" and selling prescription drugs online has been jailed for six years, according to Essex Police. The convict, identified as 49-year-old Christopher Depp, aka David Jones, was supplying a range of drugs from his home to "vulnerable people" using the postal service, local police revealed on Friday (February 16). Police conducted a search operation at his address in Wood Street, Chelmsford, in July last year and found more than 50,000 pills and tablets of varying types, stashed in toolboxes and spaces around the property. To process the large-scale sale and shipping of controlled drugs across the UK, Depp had set up a room in his property as an office space. He promoted the sale of medications through various social media platforms and messaging applications, and accepted payment from his large customer base using "fraudulently obtained" bank accounts.

Over a century-year-old Boots pharmacy in St James's Street, Brighton shut its doors permanently on Saturday (20 January) leaving the communities disappointed. The branch in Kemp Town, which was opened to the public for the first time in 1914, was supposed to close on November 19 last year but continued trading into the new year, The Argus reported. Locals are not happy with the retailer's decision to close the store as some say it used to be "always busy with prescriptions and people buying things." Another person recalled that Boots had earlier closed two pharmacies, one on Lewes Road, Brighton, and another on Church Road, Hove. The American-owned health and wellbeing chain is in the process of closing more UK branches in the coming months as it's targeting to reduce its store portfolio to 1,900 from 2,200.

A 7-year-old boy from South port, who was born with a medical condition that restricts his ability to play with his friends, is set to have much more fun in the playground thanks to receiving a Specialist Tricycle. Matthew Evans, who has Kabuki Syndrome, a condition which left him with a narrowing aorta in his heart, and weak muscle tone in his legs, was unable to walk until he was 3½-years-old. Although he can now walk by himself he can be unsteady on his feet.Buy online Tricycle for Disabled People and disabled at lowest price and cheap cost in india from wheelchair india online shopping store of Tricycle manufacturer, distributor, dealer and supplier of variety of Tricycles at low price in india for handicapped 10169.13 Matthew Evans tricycle - document As a result he's found it difficult to play outside with other children, often having to watch them from indoors. Matthew's mum, Kathryn, explained that the tricycle has had an immediate impact on her sons quality of life: "He's taken to it so well. Until now the lack of power in his legs made him unable to pedal. But the new tricycle has been engineered to make pedalling that much easier, and now he pedals everywhere with a huge smile on his face." The tricycle has a steering rod which enables Kathryn, along with dad Frank, to steer whilst Matthew puts in the leg work; further developing the muscle tone in is limbs. Kathryn explained that it's not just about physical development: "Obviously, the more Matthew uses the tricycle the more strength he will develop in his legs, however, it's also making him a more confident boy. He's pushing himself to go faster and he's now much more involved with other children. He's competing against them, so the tricycle is improving him both physically and emotionally." Wheelchair india is manufacturer, supplier, distributor and dealer of Standard Single Hand Drive Tricycle For Disabled and handicapped in india Matthew's 4-year-old sister, Laura, is also be

The full-time equivalent community pharmacy workforce saw a 6 per cent decline in a year, while the overall number of pharmacists remains nearly constant, according to NHS England's Community Pharmacy Workforce Survey 2022. However, vacancy rates among pharmacists rose 16 percent, suggesting an increased reliance on locum pharmacists who, on average, work fewer hours, the data revealed. According to NHSE, the mandated survey released (Aug. 3) achieved a 95 per cent completion rate among pharmacy contractors, marking a substantial increase compared to only 47 per cent in the previous year. The survey results indicate a shift in working patterns within community pharmacy, with locum pharmacists being utilised more frequently as part of the staffing model. The survey revealed a 6 per cent decrease in the community pharmacy workforce across all roles combined. The number of full-time equivalent pharmacists working in community pharmacy decreased by 2,411, from 20,255 in 2021 to 17,844 in 2022, the survey found. The employed pharmacists decreased by 16 per cent from 12,774 in 2021 to 10,943 in 2022, while locum pharmacists increased by 26 per cent from 4,297 in 2021 to 5,477 in 2022, NHSE said.

The British Generic Manufacturers Association (BGMA) has warned of the significant implications for future supply as a result of the crippling VPAS rate. The warning comes after the association's judicial review into the Government's decision to bar it from being a full part of the negotiations for the next five-year VPAS period was dismissed. The voluntary scheme for branded medicines pricing and access (VPAS) is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1%, but in 2023 it has soared to 26.5%. All biosimilars and a proportion of the generics market falls into the scheme.

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

Blackthorn Pharmacy in Southampton, Hampshire has been sold to expanding operator, Rosechem Limited, which has multiple other pharmacies in Hampshire and Surrey for an undisclosed amount. This health centre pharmacy dispenses an impressive average of 25,000 items per month. It has been owned by Patrick Stephens for over 25 years and was recently brought to market to allow him to retire. Patrick Stephens, previous owner of Blackthorn Pharmacy, commented: "Over the years, with a lot of hard work and support of my pharmacy team, the business had grown significantly and, after 25 years, I was keen to retire and for someone to take over my business. I am sure the buyer will be successful and will continue to grow the business and build on the great relationships we have created. I would like to thank Jonathan at Christie & Co for all his hard work and am delighted that the sale has now completed."

Men can now have their blood pressure checked while visiting a barbershop. The NHS is extending its blood pressure screening services to different local venues, including barbershops, mosques, and pharmacies. This initiative aims to address the increasing risk of strokes and heart attacks among men. NHS staff's life-saving actions coincide with recent data indicating that high street pharmacies administered 149,865 blood pressure checks to individuals over 40 in May 2023. This marked a notable increase from the previous year's count of 58,345 in May 2022, the NHS said. "More than 1,300 heart attacks and strokes could be prevented this year thanks to the high street checks." "The total number of blood pressure checks delivered by pharmacy teams in the year to March was more than 1 million (1,053,278)," the NHS added. Furthermore, the government has committed £645 million for a range of added pharmaceutical services. This includes a target of conducting 2.5 million extra blood pressure checks annually at community pharmacies. This effort is estimated to avert over 1,350 cardiovascular events per year - equivalent to averting 113 heart attacks and strokes each month.

The University of Lincoln has clinched the top spot on The Guardian's 2024 list for pharmacy and pharmacology studies. This marks a significant advancement from its second-place position in the 2023 rankings, where Ulster University had secured the leading position. Interestingly, Ulster has moved down to claim the second spot this year. Forty universities were assessed using eight criteria, which encompass student satisfaction with teaching, the effectiveness of feedback from instructors, student-to-staff ratio, expenditure per student (excluding academic staff costs), and the average UCAS scores of entrants under 21. Also included were the effectiveness of teaching methods, the proportion of students securing graduate-level employment or pursuing further studies within 15 months of graduation, and the percentage of first-year students progressing into their second year. Among the 40 universities in the ranking list, the University of Lincoln achieved a perfect score of 100 out of 100, followed by Ulster (96.2), Portsmouth (87.9), Leeds (86.3), Glasgow (85.7), Sunderland (84.3), St George's (84.3), Aberdeen (81.3), UCL (81), and Queen's, Belfast (80.1).

The Pharmaceutical Services Negotiating Committee (PSNC) has reminded Community pharmacy contractors to ensure that the correct flu vaccines are being used for each patient cohort. The pharmacies have also been asked to ensure that they recorded accurately in the patient's clinical record for the NHS Flu Vaccination Service. The move was followed by PSNC after the cases where the standard egg-cultured quadrivalent influenza vaccine (QIVe) was administered in the 65 years and over patient cohort. PSNC said: "On investigation, it appears that a number of these errors are due to data input errors; however, it is important to be careful when selecting a flu vaccine for this patient cohort as there is no provision for the use of the QIVe vaccine in patients aged 65 years and over in the NHS Flu Vaccination Service." The Joint Committee on Vaccination and Immunisation has advised it is not an effective intervention for patients aged 65 years and over.

Boots UK is set to start recruiting for a new superintendent pharmacist as Marc Donovan moved into a new role. The company announced the appointment of Anne Higgins as the new pharmacy director for Boots UK. A Boots veteran for 25 years, she has been in the role of director for stores for more than two years since starting her journey as a pre-register pharmacist in July 1997. Marc Donovan will be moving into the new role of director of healthcare development and public affairs for Boots. Earlier this year Donovan was appointed the Order of the British Empire (OBE) "for services to pharmacy" in the Queen's Birthday Honours list. Donovan and Higgins will be reporting to Jamie Kerruish, the director of healthcare at Boots UK. A Boots spokesperson told Pharmacy Business: "We will be recruiting for a new superintendent pharmacist and once this appointment is made, Marc will hand over his superintendent responsibilities"

All companies must send their accounts to Companies House each year. Recent evidence suggests that UK companies are increasingly struggling to file their accounts on time, with around 213,000 private companies reportedly missing their deadline in 2019-2020, resulting in over £93 million of penalties being issued. Over a fifth of companies that filed their accounts late that year had also filed late in the previous year. Under the Companies Act 2006 ("the Act"), the deadline for private companies to file their annual accounts is nine months from the end of the accounting reference period. There are slightly different rules for filing your first set of annual accounts and if these cover a period of more than 12 months, you must deliver them to Companies House within 21 months of the date of incorporation or 3 months from the accounting reference date, whichever is longer. Not filing your accounts at Companies House in a timely manner is also a criminal offence (under section 451 of the Act) and directors can be personally fined in the criminal courts. It is likely to come as a shock to most company directors who receive a summons to attend the Magistrates' Court in Cardiff for a criminal prosecution, particularly directors in larger pharmacy companies where directors are often detached from the preparation of accounts and senior financial staff and accountants are instructed to take care of such matters.

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

Novartis on Wednesday (February 1) predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4 per cent to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya. Novartis said it was on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its focus on its patented prescription medicines. Analysts have welcomed a programme unveiled in 2022 to trim costs and cut 8,000 jobs and plans to focus on fewer therapy areas and drug technologies. But the market has been underwhelmed by prospects for medium-term growth from new drugs.

HubRx has appointed Dr Sarah Passmore as superintendent pharmacist ahead of launching what the company called "the UK's first state-of-the-art automated pharmacy hub". Dr Passmore brings more than 20 years of pharmacy experience - having held key regulatory roles with Rowlands Pharmacy over a 11-year tenure, which also saw her involved in a number of pharmacy automation projects. Commenting on her appointment, Dr Passmore said: "As a pharmacist, who has spent more than 10 years working within community pharmacy, I'm excited by what a hub and spoke model for prescription dispensing can bring. "Pharmacists are highly trained in delivering clinical services to patients - and like me - it's often a part of their job that they thoroughly enjoy. The option of using hub and spoke to support dispensing prescriptions will give community pharmacists the gift of more time that can be spent helping patients. "I'm excited to join HubRx and for it to become the first state-of-the-art automated pharmacy hub designed for independent community pharmacists to launch in the UK."

New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer health division Haleon. After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of strong results. The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy. Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain around U.S. litigation over heartburn drug Zantac. Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.

The NHS has secured a deal for 'Pembrolizumab' to treat women with triple-negative breast cancer. Up to 1,600 women a year affected by high risk triple-negative breast cancer are set to benefit from the confidential deal struck by the NHS and the Merck Sharp and Dohme's (MSD), manufacturer of Pembrolizumab. Triple-negative breast cancer affects around 8,000 women a year - accounting for 15% of all breast cancer cases. This will be the 25th breast cancer treatment fast-tracked to patients through funding from the Cancer Drugs Fund and the second treatment for triple negative breast cancer to be introduced this year on the NHS. NHS chief executive, Amanda Pritchard, said: "This is a hugely significant moment for women - the NHS has struck a new deal to roll out a potentially life-saving drug for patients suffering with the most aggressive form of breast cancer that has been traditionally very difficult to treat.